• Pre-eclampsia is a condition in pregnant women marked by an increase in blood pressure and protein in urine after 20 weeks gestation.
• Providing high quality antenatal care improves the prevention and early detection of pre-eclampsia and can prevent its progression to eclampsia.
• Eclampsia is a life-threatening condition characterized by convulsions in women with pre-eclampsia.
• Women in developing countries are 300 times more likely to die from eclampsia than women in developed countries.
• Prescribing low-dose aspirin and calcium to at-risk women can lower their risk of developing pre-eclampsia and eclampsia.
• Severe pre-eclampsia can be managed by administering anti-hypertensive drugs and magnesium sulphate (MgSO 4 ).
• MgSO 4 is the safest and most effective treatment for severe PE/E.
• Pre-eclampsia and other hypertensive disorders in pregnancy increase the risk of preterm births, which can lead to low birth weight, anemia, and stunting.
• Improved prevention, increased detection, and effective treatment of PE/E can prevent unnecessary maternal and newborn deaths.
PE/E in Brief THE PROBLEM
Each day around the world, 830 women die from pregnancy-and childbirthrelated causes. In sub-Saharan Africa, 200,000 women die annually, and in Southern Asia 66,000 die each year. The second most common cause (after postpartum hemorrhage) is pre-eclampsia and eclampsia (PE/E)-lifethreatening, high blood pressure and excess protein in the urine after 20 weeks gestation. These deaths are preventable, yet essential medicines and tools to treat this disorder are often unavailable in low-resource settings.
PE/E most often occurs during the second half of pregnancy, but can happen before, during, or after delivery. It can lead to seizures, kidney and liver damage, and death, and increases the risk of preterm births, low birth-weight, anemia, and stunting. Women who have PE/E have an increased risk of developing cardiovascular disease and other non-communicable diseases in later life.
The World Health Organization (WHO) recommends magnesium sulphate (MgSO 4 ) as the most effective, safe, and low-cost anticonvulsant treatment for severe pre-eclampsia and eclampsia. Twenty-eight countries include MgSO 4 on their Essential Medicines List and have protocols on its use, but in practice, the drug is often unavailable at community facilities or is not used in compliance with guidelines. The second phase of the intervention (2012-2014) focused on primary health care (PHC) facilities, specifically on training PHC providers to administer a modified loading dose of MgSO 4 (intra-muscular only) and refer women to secondary health facilities for monitoring. PHC providers received continued technical support from trainings and routine mentorship.
PHC PE/E CORE MODEL DEVELOPMENT
The Council conducted an implementation research study to evaluate this task shifting process around the prevention, detection, and management of PE/E at the PHC level, hereby defined as the PHC PE/E Core Model. The study showed that not only were PHC providers effectively able to carry out this task, but maternal mortality in the intervention group decreased.
These components: Training PHC providers on detection and management of PE/E, administration of a loading dose of MgSO 4 , referral of women to secondary facilities for monitoring, and reinforcing proper detection and management of PE/E at secondary facilities are included in the PHC PE/E Core Model (Figure 1).
The Ending Eclampsia project seeks to expand access to proven,underutilized interventions and commodities for the prevention, early detection, and treatment of pre-eclampsia and eclampsia and strengthen global partnerships.
SCALE UP OF PHC PE/E CORE MODEL
The primary goal of the Ending Eclampsia project is to expand the use of MgSO 4 and other underutilized commodities and strategies to prevent and treat preeclampsia and eclampsia (PE/E). Collaborating with national policymakers, ministries of health, community leaders, and health providers to increase access to highimpact, low-cost interventions.
The Ending Eclampsia project has been implementing the PHC PE/E Core Model in select regions in Bangladesh, Nigeria, and Pakistan. Replicating the core activities was crucial to demonstrate that the PHC PE/E Core Model is acceptable and feasible in varied settings. Prior to initiating implementation of the PHC PE/E Core Model, any organization--whether a ministry of health, an international non-governmental organization, or a local organization--must consider the reality on the ground within the particular context. Monitoring data and preliminary analyses across these three countries indicate that task shifting of oral antihypertensive drugs to PHCs is feasible and effective.
For the PHC PE/E Core Model to be the most effective (Figure 1) 
Engaging community women's groups (Nigeria)
Women's group leaders were trained on health information that focused on antenatal care (ANC) and postnatal care (PNC) using a simplified pictorial job aid and log book to record activities.
Trained women's group leaders provide health education and information to their peers during their regular meetings. The expectation is that in doing so, more women will be empowered to use health facilities for themselves or to encourage their relatives for ANC/ PNC. In this way, ANC attendance, pre-eclampsia case detection and management, and quality of care for other services will improve. Figure 1) Task-shifting to community midwives (Pakistan)
Community groups with women, men, or a mix of the genders, can be targeted as channels for sharing important health information with communities (
Through implementation research conducted in Pakistan, researchers are assessing community midwives' (CMWs) ability to screen and detect PE/E cases, to provide a modified loading dose of MgSO 4 to the appropriate clients, and to refer them for further management.
In addition, this study aims to enhance the collaboration between CMWs and local health workers (LHWs) by encouraging LHWs to refer pregnant women for group ANC sessions provided by local CMWs, and to improve ANC and PNC counselling skills of CMWs so as to enable them to manage postpartum hypertension.
Explore postnatal outcomes
About 25% of women with hypertensive disorders in pregnancy (HDPs), especially those with a severe condition, experience a deterioration of end organ functions during puerperium (period spanning 6 -8 weeks after delivery).In Bangladesh and Nigeria, Ending Eclampsia researched health outcomes of women and newborns after pregnancies complicated by HDPs and followed up with them at nine weeks, six months and one year after delivery to evaluate the nature of care they received, assess their health status, and identify any patterns in development of morbidities.
Trained nurses and midwives at the maternity unit conduct follow ups, which include reviewing treatment records from delivery onward, performing routine medical checkups, and surveying participants. 
NEXT STEPS
Detailed results of the Ending Eclampsia project in each country will be available in 2019. Cross-country learnings will further refine the PHC PE/E plus Model as a framework for global policy, program, and research strategies to address the problem of hypertension in pregnancy in a context-sensitive way. A package of step-wise recommendations around task-shifting will be compiled and disseminated for integration within country-level maternal health strategies. At regional and global levels, Ending Eclampsia plans to share the PHC PE/E plus model, related findings, and tools for adoption and scale up in varied settings.
